Smoking is associated with reduced serum levels of the antioxidant enzyme, paraoxonase, in Type 2 diabetic patients

Diabetic Medicine

Volumn 21, Issue 5, 2004, Pages 423-427

  Boemi, M ^a   Sirolla, C ^a   Testa, R ^a   Cenerelli, S ^a   Fumelli, P ^a   James, R W ^b  

^a Diabetology Unit   (Italy)

^b UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

HDL; Lipoproteins; Oxidative stress; Risk factor

Indexed keywords

ANTIOXIDANT; ARYLDIALKYLPHOSPHATASE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; SMOKING HABIT; SWITZERLAND;

AGED; AGED, 80 AND OVER; ARYLDIALKYLPHOSPHATASE; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; REGRESSION ANALYSIS; RISK FACTORS; SMOKING;

EID: 2342589339     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2004.01163.x     Document Type: Article

References (30)

1. Mackness MI, Arrol S, Abbot C, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993; 104: 129-35.
2. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parma SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998; 101: 1581-90.
3. Shih DM, Gu L, Xia Y-R, Navab M, Li W-F, Hama S et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998; 394: 284-7.
4. Shih DM, Xia YR, Wang XP, Miller E, Castellani LW, Subbanagounder G et al. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem 2000; 275: 17527-35.
5. Ruiz J, Blanché H, James RW, Blatter MC, Charpentier G, Morabia A et al. The polymorphism (Gln-Arg192) of the high-density lipoprotein-bound enzyme paraoxonase is an independent cardiovascular risk factor in non-insulin dependent diabetic patients. Lancet 1995; 346: 869-72.
6. Serrato M, Marian AJ. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary heart disease. J Clin Invest 1995; 96: 3005-8.
7. Blatter Garin M-C, James RW, Dussoix P, Blanché H, Passa P, Froguel P et al. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest 1997; 99: 62-6.
8. 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler Thromb Vasc Biol 1997; 17: 3565-69.
9. Pfohl M, Koch M, Enderle MD, Kühn R, Füllhase J, Karsch KR et al. Paraoxonase 192 Gln/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes. Diabetes 1999; 48: 623-7.
10. James RW, Leviev I, Righetti A. Smoking is associated with reduced serum paraoxonase activity and concentration in coronary artery disease patients. Circulation 2000; 101: 2252-7.
11. Leviev I, Righetti A, James RW. Paraoxonase promoter polymorphism T(-107)C and relative paraoxonase deficiency as determinants of risk of coronary artery disease. J Mol Med 2001; 79: 457-63.
12. Nishio E, Watanabe Y. Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme's free thiols. Biochem Biophys Res Commun 1997; 236: 289-93.
13. Senti M, Aubo C, Tomas M. Differential effects of smoking on myocardial infarction risk according to the Gln/Arg 192 variants of the human paraoxonase gene. Metabolism 2000; 49: 557-9.
14. Malin R, Loimaala A, Nenonen A, Mercuri M, Vuori I, Pasanen M, et al. Relationship between high-density lipoprotein paraoxonase gene M/L55 polymorphism and carotid atherosclerosis differs in smoking and non-smoking men. Metabolism 2001; 50: 1095-101.
15. Boemi M, Leviev I, Sirolla C, Pieri C, Marra M, James RW. Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation. Atherosclerosis 2001; 155: 229-35.
16. Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 1995; 15: 1812-18.
17. Hedrick CC, Thorpe SR, Fu MX, Harper CM, Yoo J, Kim SM et al. Glycation impairs high-density lipoprotein function. Diabetologia 2000; 43: 312-20.
18. Inoue M, Suehiro T, Nakamura T, Ikeda Y, Kumon Y, Hashimoto K. Serum arylesterase/diazoxonase activity and genetic polymorphisms in patients with type 2 diabetes. Metabolism 2000; 49: 1400-5.
19. Kordonouri O, James RW, Bennetts B, Chan A, Kao YL, Danne T et al. Modulation by blood glucose levels of activity and concentration of paraoxonase in young patients with type 1 diabetes mellitus. Metabolism 2001; 50: 657-60.
20. Mackness B, Durrington PN, Boulton AJ, Hine D, Mackness MI. Serum paraoxonase activity in patients with type 1 diabetes compared to healthy controls. Eur J Clin Invest 2002; 32: 259-6.
21. Jarvik GP, Rozek LS, Brophy VH, Hatsukami TS, Richter RJ, Schellenberg GD et al. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler Thromb Vasc Biol 2000; 20: 2441-7.
22. Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E et al. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 2001; 21: 1451-7.
23. Leviev I, James RW. Promoter polymorphisms of the human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 2000; 20: 516-21.
24. Suehiro T, Nakamura T, Inoue M, Shiinoki T, Ikeda Y, Kumon Y et al. A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. Atherosclerosis 2000; 150: 295-8.
25. Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, Furlong CE. Effects of 5′ regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet 2001; 68: 1428-36.
26. Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL et al. Human serum paraoxonase (PON1) is inactivated by oxidised low density lipoprotein and preserved by antioxidants. Free Rad Biol Med 1999; 26: 892-904.
27. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999; 48: 1-9.
28. Pryor WA, Stone K. Oxidants in cigarette smoke. Radicals, hydrogen peroxide, peroxynitrate and peroxynitrite. Ann NY Acad Sci 1993; 686: 12-27.
29. Dallongeville J, Marecaux N, Fruchart J-C, Amouyel P. Cigarette smoking is associated with unhealthy patterns of nutrient intake: a meta-analysis. J Nutr 1998; 128: 1450-1457.
30. Pryor WA, Stone K, Zang LY, Bermudez E. Fractionation of aqueous cigarette tar extracts: fractions that contain the tar radical cause DNA damage. Chem Res Toxicol 1998; 11: 441-448.